AGM
NRXP icon

Alpine Global Management’s NRX Pharmaceuticals NRXP Stock Holding History

Alpine Global Management’s Portfolio NRXP Stock Details NRXP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-2,533
Closed -$121K – 630
2021
Q4 		$121K Buy
+2,533
New +$183K 0.02% 618

Other funds holding NRXP

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Alpine Global Management's NRXP Position: Q1 2022 in Review

Alpine Global Management sold out of NRX Pharmaceuticals (NRXP) in Q1 2022, closing a stake of 2,533 shares — an estimated $121K sold.

Alpine Global Management first reported a position in NRXP in Q4 2021 and held it in 1 quarter. The position peaked at $121K in Q4 2021. 34 funds tracked by Wall St. Rank hold NRXP as of Q1 2022.

  • Alpine Global Management reported no remaining NRX Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
  • Alpine Global Management sold 2,533 NRX Pharmaceuticals shares in Q1 2022, an estimated $121K.
  • Alpine Global Management first reported a position in NRX Pharmaceuticals in Q4 2021 and held it in 1 quarter.
  • Alpine Global Management's NRX Pharmaceuticals position peaked at $121K in Q4 2021.
  • 34 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q1 2022.

Based on Alpine Global Management's 13F filing for Q1 2022, filed 13 May 2022.